{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["197(3)"],"submitter":["Ujjani C"],"funding":["Fred Hutchinson Cancer Research Center","Andy Hill CARE Fund"],"pubmed_abstract":["Prior reports evaluating SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia (CLL) used semiquantitative measurements of anti-S to evaluate immunity; however, neutralization assays were used to assess functional immunity in the trials leading to vaccine approval. Here, we identified decreased rates of seroconversion in vaccinated CLL patients and lower anti-S levels compared to healthy controls. Notably, we demonstrated similar results with the Roche anti-S assay and neutralization activity. Durable responses were seen at six months; augmentation with boosters was possible in responding patients. Absence of normal B cells, frequently seen in patients receiving Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors, was a strong predictor of lack of seroconversion."],"journal":["British journal of haematology"],"pagination":["306-309"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9111753"],"repository":["biostudies-literature"],"pubmed_title":["The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia."],"pmcid":["PMC9111753"],"pubmed_authors":["Sorensen T","Lee S","Huang ML","Tu B","Smith SD","Hill JA","Lynch RC","Zhu H","Till BG","Ujjani C","Stevenson PA","Grainger C","Warren EH","Shadman M","Gausman D","Poh C","Gopal AK","Nielsen L","Greninger A","Gooley T"],"additional_accession":[]},"is_claimable":false,"name":"The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.","description":"Prior reports evaluating SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia (CLL) used semiquantitative measurements of anti-S to evaluate immunity; however, neutralization assays were used to assess functional immunity in the trials leading to vaccine approval. Here, we identified decreased rates of seroconversion in vaccinated CLL patients and lower anti-S levels compared to healthy controls. Notably, we demonstrated similar results with the Roche anti-S assay and neutralization activity. Durable responses were seen at six months; augmentation with boosters was possible in responding patients. Absence of normal B cells, frequently seen in patients receiving Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors, was a strong predictor of lack of seroconversion.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-05-31T20:59:49.529Z","creation":"2025-02-19T04:21:04.195Z"},"accession":"S-EPMC9111753","cross_references":{"pubmed":["35149986"],"doi":["10.1111/bjh.18088"]}}